Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$23.8M | -$57.9M | -$50.7M | -$43.1M | -$59.6M | -$61.1M | -$42.1M | -$62.1M |
| Net income | -$23.2M | -$55.2M | -$50.0M | -$42.9M | -$58.4M | -$59.7M | -$41.5M | -$63.1M |
| EPS (diluted) | $72.63 | -$3.50 | -$1.70 | -$1.02 | -$1.38 | -$1.39 | -$0.67 | -$0.75 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.0M | -$51.2M | -$50.7M | -$33.2M | -$52.5M | -$46.4M | -$28.8M | -$49.0M |
| Capital expenditures | $5.00K | $413K | — | — | $272K | $112K | $33.0K | $302K |
| Free cash flow | -$21.1M | -$51.6M | — | — | -$52.7M | -$46.5M | -$28.9M | -$49.3M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $85.9M | $120M | $72.3M | $114M | $7.64M | $13.8M | $25.3M | $73.0M |
| Total assets | $88.1M | $123M | $150M | $120M | $74.5M | $75.2M | $75.5M | $114M |
| Total liabilities | $4.53M | $8.51M | $6.86M | $7.25M | $8.13M | $58.5M | $62.4M | $71.8M |
| Long-term debt | — | $0.00 | — | — | — | $49.8M | $53.4M | $57.2M |
| Shareholders' equity | $83.5M | $115M | $143M | $113M | $66.3M | $16.8M | $13.1M | $41.8M |
| Retained earnings | -$58.3M | -$113M | -$163M | -$208M | -$266M | -$326M | -$368M | -$431M |
| Shares (wtd avg diluted) | 597K | 24.5M | 29.8M | 29.9M | 34.3M | 33.5M | 53.4M | 106M |
Every figure is extracted from Milestone Pharmaceuticals Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.